Acquisition - March 12, 2015
AstraZeneca Buys More Respiratory Business
AstraZeneca recently acquired the rights to Actavis’ branded respiratory business in the US and Canada, according to a company announcement. As part of the agreement, AstraZeneca is paying Actavis $600 million of initial consideration and agreed to pay low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Actavis an additional $100 million for […]
Agreement - July 30, 2014
AstraZeneca signs deal with Almirall
AstraZeneca agrees strategic transaction with Almirall in respiratory disease. AstraZeneca has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. Also, AstraZeneca has agreed to make various sales-related payments. Upon completion […]
Agreement - April 1, 2014
Index Pharmaceuticals signs deal with Almirall
The two companies have entered into a license agreement for European rights of the phase III drug candidate Kappaproct.
